drugset / Trial / NCT07625384
Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of the study is to evaluate the efficacy and safety of goflikicept (GFC) and olokizumab (OKZ) in patients with Still's disease
Timeline
- Start
- 2026-05-18
- Primary completion
- 2027-12-14
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Goflikicept | Monoclonal antibody | 160 mg | Intravenous |
| Subject | Olokizumab | Monoclonal antibody | 64 mg | Intravenous |
Indications
No indication recorded.